Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Dianthus Therapeutics (NASDAQ:DNTH) has received an average consensus recommendation of "Buy" from nine research firms, with the average 12-month price target set at approximately $61.57.
• The company reported a negative earnings per share of ($0.88), missing analyst expectations, and had revenue of only $0.19 million for the quarter, compared to a forecast of $0.87 million.
• Institutional investors and hedge funds own 47.53% of Dianthus Therapeutics' stock, with significant increases in holdings by firms like Vestal Point Capital and RA Capital Management.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been assigned an average recommendation of "Buy" from the nine research firms that are currently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have covered the stock in the last year is $61.5714.

A number of brokerages have commented on DNTH. Guggenheim increased their price objective on Dianthus Therapeutics from $92.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, September 9th. Stifel Nicolaus lifted their price objective on Dianthus Therapeutics from $52.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, September 12th. William Blair initiated coverage on Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an "outperform" rating for the company. Raymond James Financial reaffirmed an "outperform" rating and issued a $63.00 target price (up previously from $56.00) on shares of Dianthus Therapeutics in a research note on Tuesday, September 9th. Finally, Wedbush boosted their price target on shares of Dianthus Therapeutics from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Friday, September 12th.

Dianthus Therapeutics Stock Up 2.4%

Shares of NASDAQ:DNTH opened at $36.71 on Friday. The firm has a market cap of $1.18 billion, a P/E ratio of -11.30 and a beta of 1.46. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $39.87. The company's 50-day moving average price is $26.54 and its two-hundred day moving average price is $21.59.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. As a group, equities analysts predict that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.15% of the company's stock.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of DNTH. Vestal Point Capital LP increased its holdings in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the period. RA Capital Management L.P. raised its position in shares of Dianthus Therapeutics by 53.6% in the 1st quarter. RA Capital Management L.P. now owns 2,866,733 shares of the company's stock valued at $52,003,000 after buying an additional 1,000,333 shares in the last quarter. Candriam S.C.A. acquired a new position in shares of Dianthus Therapeutics in the 1st quarter valued at approximately $4,510,000. Octagon Capital Advisors LP lifted its holdings in shares of Dianthus Therapeutics by 11.0% during the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company's stock worth $42,478,000 after acquiring an additional 231,500 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock worth $21,887,000 after acquiring an additional 149,200 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.